Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Philadelphia, PA 19104Phone+1 215-579-1300Fax+1 215-662-7011
Summary
- Dr. Daniel Pryma, MD is a board certified nuclear medicine physician in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and New York.
Education & Training
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
PA State Medical License 2005 - 2026
NJ State Medical License 2014 - 2025
NY State Medical License 2003 - 2016
IL State Medical License 2002 - 2003
American Board of Nuclear Medicine Nuclear Medicine
Publications & Presentations
PubMed
- [F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.Joanna K Weeks, Austin R Pantel, Sarah B Gitto, Fang Liu, Erin K Schubert
Journal of Nuclear Medicine. 2025-01-03 - Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-TargetedF-Fluorthanatrace PET in Breast Cancer.Anthony J Young, Austin R Pantel, Mahsa Kiani, Robert K Doot, Sina Bagheri
Journal of Nuclear Medicine. 2024-12-03 - 6 citationsPrimary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using MidtreatmentF-Fluorodeoxyglucose Posi...Feng-Ming Spring Kong, Chen Hu, Daniel A Pryma, Fenghai Duan, Martha Matuszak
Journal of Clinical Oncology. 2024-11-20
Press Mentions
Neuroendocrine Cancer Program: Not a Rare Cancer at Penn MedicineOctober 4th, 2021- Awards & Accolades: May 2021June 9th, 2021
Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (Iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or ParagangliomaSeptember 17th, 2018- Join now to see all
Grant Support
- Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancerUNIVERSITY OF PENNSYLVANIA2023–2028
